Diabetes, weight and hormones
383 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 0.75% Phentolamine Ophthalmic Solution for vitamin a deficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Agbs for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AI-Guided Multimodal Rehabilitation Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Alcohol beverage for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aminohippurate Sodium Inj 20% + CANAGLIFLOZIN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 100 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 125 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 150 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg BID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AP306 75 mg TID for hyperphosphatemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apitegromab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| arabinoxylan for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ARBs in combination of SGLT2i for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATR-258 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATR-258 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + EVOLOCUMAB for hyperlipoproteinemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autoinjector + Maridebart Cafraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for glucose metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Avexitide for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| AZD6234 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AZD6234 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Barley beta-glucan(3.0g) for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Barley beta-glucan(3.0g) for overweight | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baxdrostat for hyperaldosteronism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| BBI-001 for hemochromatosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BEAM-301: Single dose of BEAM-301 administered by IV for glycogen storage disease type i | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berberine ursodeoxycholate for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Berobenatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Berobenatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beta glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Beta-glucan addition to a restricted calorie of meal replacements and carbohydrate diet. for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 1820237 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 1820237 + Placebo for BI 1820237 + Placebo for BI 456906 + Survodutide for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BI 3034701 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bimagrumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| bis-octanoyl (R)-1,3-butanediol (C8 ketone di-ester) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood and adrenaline for severe acute malnutrition | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Body Composition + Blood Draw + CGM/CKM + gradCPT + Ketogenic Diet + Ketone/Glucose Monitoring + NIH Toolbox + PHQ-9 + Resting-state fMRI + SKID + Sleep Monitoring + Task-fMRI + WHO-5 for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for hyperglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bread with added beta-glucans for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cagrilintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cagrilintide and Semaglutide + Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CagriSema (Cagrilintide B + semaglutide I) for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CagriSema (Cagrilintide B + semaglutide I) + Low Energy Diet for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restricted diet and exercise intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restriction via total food replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Calorie restriction via total food replacement for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cfMSC therapy for diabetes for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cholecalciferol for vitamin d deficiency | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ci + ends for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI + No ENDS for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CIL001 (Paliroden) for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clazakizumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clofutriben for cushing syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clofutriben for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Comprehensive weight loss + Enhanced lifestyle changes + Naltrexone-Bupropion + Phentermine-Topiramate for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Comprehensive weight loss + Enhanced lifestyle changes + Semaglutide + Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Continous Glucose Monitor (CGM) + Low-calorie diet + Personalized exercise program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Control for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CoolSculpting® System for lipid metabolism disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Phone calls + Self-monitoring tools + Text Messages for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cryolipolysis for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| cryolipolysis and aerobic exercise for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cryolipolysis device for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for homozygous familial hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTX310 for hyperlipoproteinemia type v | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Culturally Tailored Diabetes Prevention Program + Culturally Tailored DPP Enhanced with Socioeconomic Supports for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cyanocobalamin for vitamin b 12 deficiency | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danuglipron for diabetes mellitus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Danuglipron for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin + Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin plus Glucophage (MET ER) for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dapagliflozin propanediol for iron deficiencies | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| delayed APM group recruit participants with symptoms lasting for more than 6 months for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Desiccated Porcine Thyroid Extract Tablets for hypothyroidism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + INSULIN HUMAN for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Sliding Scale Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexcom G6 Professional Continuous Glucose Monitor + Up-Titration of Home Insulin for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet Management + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet-as-Usual (DAU) + LCHF Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dietary vitamin D for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Digital Intervention + Metformin for prediabetic state | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| digital prosthetic interface technology for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DMR Procedure (Fractyl) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DR10624 Injection for hypertriglyceridemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Dulaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Early arthroscopic partial menisectomy group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for iron overload | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ecnoglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Efzimfotase Alfa for hypophosphatasia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elecoglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Elecoglipron for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Electronic Cigarettes (EC) for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Eloralintide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 13 |
| Eloralintide + Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Eloralintide + Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eloralintide + Tirzepatide for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| eloralintide and tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| eloralintide and tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Empagliflozin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Empagliflozin for ketosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Empagliflozin for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ends + ni for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Chloride for hypercholesterolemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Enlicitide Decanoate for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Enlicitide Decanoate for hyperlipoproteinemia type ii | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| EQW plus DAPA for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Evolocumab for hypercholesterolemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Exenatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exercise for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exploratory test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ezetimibe or ezetimibe-statin combination therapy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| fecal microbiota transplantation from healthy lean donors for metabolic syndrome | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fixed-Dose Combination Strategy for dyslipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food Security Screening & Referral Program for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food-based diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Food-based diet for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formula diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formula diet for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Formulation A + Formulation B6 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Freshly reconstituted MDCF-2 ingredients for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GnRH antagonist + Letrozole for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee + beta-glucan for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee + beta-glucan for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee extract for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green coffee extract for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + naltrexone and bupropion (combination) for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Phentermine-Topiramate for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Group Therapy Program + Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| gut-brain axis (GLP-1)-activating food carbohydrate for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GVHD prophylaxis regimen + RIC regimen for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Haploidentical Hematopoietic Cell Transplantation for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 25mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HD-6277 50mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-intensity Mediterranean diet intervention for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Home Based Physical Exercise + Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HRS9531 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| HRS9531 Injection for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| HRS9531 injection;Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| HS-20094 Injection for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Hyperpolarized 13C-pyruvate for metabolic syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100 mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| icovamenib 100mg for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IN-B00009 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Inclisiran for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Insulin efsitora alfa for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 12 |
| Insulin efsitora alfa for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for prediabetic state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention + Meal replacement system for diabetes mellitus, type 2 | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensive lifestyle Intervention + Meal replacement system for obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent energy restriction (IER) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intermittent fasting 5:2 + Low-carbohydrate diet + Total diet replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intraoral Negative Pressure Therapy + Oral Appliances + Positional Therapy + Surgery + Tongue Muscle Strength Training for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivm for ovarian hyperstimulation syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 120 mg BID and K-833 100 mg BID for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 120 mg BID and matching placebo to K-833 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 BID + K-757 and K-833 QD for diabetes mellitus, type 2 | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| K-757 and K-833 BID + K-757 and K-833 QD for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Kenetik for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic Diet for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketogenic diet intervention for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laroprovstat for dyslipidemias | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LCHF Ketogenic Diet for ketosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| libitum diet and waiting list control group for metabolic syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liraglutide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Liraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Liver-expressed antimicrobial peptide 2 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lns for infant nutrition disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lns for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low calorie diet + Phentermine/topiramate for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-dose LC-Z300-01 twice daily in blinding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Macupatide for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| MAR001 for hypertriglyceridemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Maridebart Cafraglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Maridebart Cafraglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Maridebart Cafraglutide for overweight | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching placebo to K-757 and matching placebo to K-833 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Garetosmab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo-Trevogrumab + Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mazdutide for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDCF-2 shelf-stable foil pouch prototype with green banana powder for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDCF-2 shelf-stable foil pouch prototype with sweet potato for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Meal Replacement Therapy for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Meglumine sodium succinate for diabetic ketoacidosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MET097 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metreleptin for insulin resistance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MiniMed 670G system for hypoglycemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MKP10241 for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MKP10241 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified delineation for thyroid diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for acidosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| mRNA-3927 for propionic acidemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MT1013 for hyperparathyroidism, secondary | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Napazimone for mitochondrial diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neovasculgen® for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NI + No ENDS for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotine replacement therapy (NRT) for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NNC0487-0111 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| obicetrapib 10 mg + ezetimibe 10 mg FDC daily for hyperlipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Olezarsen for hyperlipoproteinemia type i | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral appliance therapy for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oral BGE-102 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Orforglipron for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 15 |
| Orforglipron for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 16 |
| Osilodrostat for adrenal hyperplasia, congenital | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Osilodrostat for cushing syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Oxytocin for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Parathyroid Allotransplant for hypoparathyroidism | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment. for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Patiromer for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemvidutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Petrelintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06882961 (Cohort 3) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06882961 (Cohorts 1 and 2) for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-08653944 for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-08653944 for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PG-102 for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for metabolism, inborn errors | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Extended Release Oral Capsule [Qsymia] for sexual infantilism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Oral Product for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine / Topiramate Oral Product for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Phentermine-Topiramate ER for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Photobiomodulation for obesity, morbid | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo (for Syntocinon) + Oxytocin for sexual infantilism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo (matched to semaglutide) + Zenagamtide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide + Macupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Eloralintide + Tirzepatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + MAZDUTIDE for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Naperiglipron for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Oxytocin for obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Reduced-calorie diet + Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Standardized diet and physical activity counseling throughout the study. + Retatrutide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo Nasal Spray for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| placebo with matching dosage + ECNOGLUTIDE for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PolyPill for hyperlipidemias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection for disorders of sex development | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex development | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for disorders of sex development | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia 11.25Mg-69Mg Extended Release Capsule + Qsymia 15Mg-92Mg Extended Release Capsule + Qsymia 3.75Mg-23Mg Extended Release Capsule + Qsymia 7.5Mg-46Mg Extended Release Capsule for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Qsymia and lifestyle management therapy for pediatric obesity | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RAY1225 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ready-to-use supplementary food (RUSF) arm for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for cushing syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relacorilant for insulin resistance | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| responsive neurostimulation for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Retatrutide for insulin resistance | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for metabolic diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Retatrutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 12 |
| Ribupatide for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RP-A501 for lysosomal storage diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Semaglutide for glucose intolerance | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 20 |
| Semaglutide for pediatric obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Semaglutide + BIMAGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide + Cagrilintide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Semaglutide + Cagrilintide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Semaglutide + TREVOGRUMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide + TREVOGRUMAB + GARETOSMAB for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sernova Cell Pouch for hypoglycemia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHR-1918 for homozygous familial hypercholesterolemia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Silkworm pupa tablets for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium zirconium cyclosilicate for hyperkalemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| standardized exercize program + Standardized nutritional program + Whey protein supplement with added leucine and β-hydroxy-β-methylbutyrate (HMB) for malnutrition | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured weight-loss program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Structured weight-loss program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sun Exposure + Vitamin D3 Supplements for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Survodutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 15 |
| Test group for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Testosterone for eunuchism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Testosterone enanthate for eunuchism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tifeglipron for diabetes mellitus, type 2 | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating (TRE) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time Restricted Eating As Treatment (TREAT) for Diabetes. for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time restricted feeding for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time-restricted eating for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Time-restricted eating for overweight | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Tirzepatide for dyslipidemias | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for metabolic syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Tirzepatide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 23 |
| Tirzepatide for prediabetic state | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Topical Simvastatin 2% Cream for xanthomatosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (800kcal/day) for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (TDR) Program for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Total Diet Replacement (TDR) Program for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tranexamic acid for iron deficiencies | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Ketone Supplement for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for ketosis | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treosulfan for nijmegen breakage syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trevogrumab for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| UBT251 Injection 2.0 mg and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 6.0 mg for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| UBT251 Injection 6.0 mg and UBT251 Injection Placebo for obesity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ultrasound lipolysis for obesity, abdominal | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Upacicalcet for hyperparathyroidism, secondary | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hypercholesterolemia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VERVE-102 for hyperlipoproteinemia type ii | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Very Low-calorie MIND-HK diet for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 for obesity, morbid | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 Mid Dose for pediatric obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 oral capsule for pediatric obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VI-0521 Top Dose for pediatric obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vicadrostat for diabetes mellitus, type 2 | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Virtual Weight Management Coaching + Semaglutide for obesity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Vitamin d for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D supplementation for diabetes mellitus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vitamin D supplementation for vitamin d deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VX-017 for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| WS016 for hyperkalemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| WVE-007 for obesity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zeltiq CoolSculpting device for obesity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zenagamtide for diabetes mellitus, type 2 | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zimislecel for hypoglycemia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |